Skip to main content
Premium Trial:

Request an Annual Quote

Nucleonics Challenges Second Benitec RNAi Patent in Australia

NEW YORK, Nov. 2 (GenomeWeb News) - Nucleonics is challenging a second RNAi patent held by Benitec and the Commonwealth Scientific and Industrial Research Organization in Australia, the Horsham, Pa.-based company said today.


Nucleonics filed a request with the commissioner of patents in Australia that the patent, Australian Innovation Patent No. 2001100608, be re-examined. The company believes the patent, entitled "Control of Gene Expression," claims lack novelty or did not involve an innovative step at the time the patent application was filed.


This is Nucleonics's third challenge of an RNAi patent held by Benitec and CSIRO within two months.  In September, it challenged another patent in Australia in October it asked the USPTO to re-examine a US patent.

The Scan

Tennessee's COVID-19 Sequencing

The Tennessean reports that a state lab there can now run its own genome sequencing analyses of SARS-CoV-2 samples.

Sanction Violation Charges

A former professor has been charged with exporting genetic sequencing equipment to Iran in violation of US sanctions, the Miami Herald reports.

Prenetics to Go Public Through SPAC

Prenetics, a Hong Kong-based genomic and diagnostic company, is going public through a SPAC merger, according to 360Dx.

Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair

In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.